

Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Non-small-cell lung carcinoma | D002289 | — | — | 3 | 9 | 4 | — | — | 15 |
| Neoplasms | D009369 | — | C80 | 7 | 2 | 2 | — | — | 11 |
| Lung neoplasms | D008175 | — | C34.90 | 1 | 7 | 1 | — | 1 | 10 |
| Carcinoma | D002277 | — | C80.0 | — | 5 | 3 | — | — | 8 |
| Renal cell carcinoma | D002292 | EFO_0000376 | — | — | 4 | 2 | — | — | 6 |
| Neoplasm metastasis | D009362 | EFO_0009708 | — | — | 1 | 1 | — | — | 2 |
| Kidney diseases | D007674 | EFO_0003086 | N08 | — | — | 1 | — | — | 1 |
| Urologic neoplasms | D014571 | — | C64-C68 | — | — | 1 | — | — | 1 |
| Kidney neoplasms | D007680 | EFO_0003865 | C64 | — | — | 1 | — | — | 1 |
| Neoplasms by site | D009371 | — | — | — | — | 1 | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Adenocarcinoma | D000230 | — | — | 1 | 5 | — | — | — | 5 |
| Stomach neoplasms | D013274 | EFO_0003897 | C16 | 1 | 2 | — | — | — | 3 |
| Colorectal neoplasms | D015179 | — | — | 1 | 1 | — | — | — | 2 |
| Prostatic neoplasms | D011471 | — | C61 | — | 1 | — | — | — | 1 |
| Clear cell adenocarcinoma | D018262 | — | — | — | 1 | — | — | — | 1 |
| Adenomyoepithelioma | D055331 | — | — | — | 1 | — | — | — | 1 |
| Colonic neoplasms | D003110 | — | C18 | — | 1 | — | — | — | 1 |
| Rectal neoplasms | D012004 | — | — | — | 1 | — | — | — | 1 |
| Mutation | D009154 | — | — | — | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 4 | — | — | — | — | 4 |
| Long qt syndrome | D008133 | HP_0001657 | I45.81 | 1 | — | — | — | — | 1 |
| Therapeutic equivalency | D013810 | — | — | 1 | — | — | — | — | 1 |
| Recurrence | D012008 | — | — | 1 | — | — | — | — | 1 |
| Glioma | D005910 | EFO_0000520 | — | 1 | — | — | — | — | 1 |
| Central nervous system neoplasms | D016543 | — | — | 1 | — | — | — | — | 1 |
| Medulloblastoma | D008527 | — | — | 1 | — | — | — | — | 1 |
| Nervous system neoplasms | D009423 | — | — | 1 | — | — | — | — | 1 |
| Diffuse intrinsic pontine glioma | D000080443 | — | — | 1 | — | — | — | — | 1 |
| Drug common name | Savolitinib |
| INN | savolitinib |
| Description | Savolitinib is an experimental small molecule inhibitor of c-Met. It is being investigated for the treatment of cancer by AstraZeneca. It is in phase II clinical trials for adenocarcinoma, non-small cell lung cancer, and renal cell carcinoma. It has been given conditional approval for these indication in China.
|
| Classification | Small molecule |
| Drug class | tyrosine kinase inhibitors |
| Image (chem structure or protein) | ![]() |
| Structure (InChI/SMILES or Protein Sequence) | C[C@@H](c1ccc2nccn2c1)n1nnc2ncc(-c3cnn(C)c3)nc21 |
| PDB | — |
| CAS-ID | 1313725-88-0 |
| RxCUI | — |
| ChEMBL ID | CHEMBL3334567 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB12048 |
| UNII ID | 2A2DA6857R (ChemIDplus, GSRS) |

